Phase 2 N=148 Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline to Week 16 in EASI Score — NA; NA; NA; NA Percentage of change from baseline — p=0.888
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=148 Impact of Progesterone on Stress Reactivity and Cannabis Use
Cannabis Use
Primary: Cannabis Craving — 3.7; 3.4; 4.3; 4.5 units on a scale
Phase 2 N=151 Efficacy and Safety of RZL-012 on Submental Fat Reduction
Submental Fat
Primary: Efficacy -Proportion of Subjects With at Least a 1-grade Improvement in the C-CAT Scale at Day 84 — 43; 39; 27 participants
Phase 2 N=114 Ramipril for the Treatment of COVID-19
COVID-19
Primary: Composite of Mortality or Need for ICU Admission or Ventilator Use — 2; 0 Participants
Phase 2 N=50 Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 — -74.45; -41.43 percent change — p=<0.001
Phase 2 N=259 Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 5.8; 18.0; 44.2…
Phase 2 N=57 Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
Prostate Cancer
Primary: Time to Progression (TTP) — 24.2; 19.1 Months
Phase 2 N=9 Glenohumeral Cortisone Injection
Humeral Fractures
Primary: American Shoulder Elbow Society Score — 46; 87 score on a scale
Phase 2 N=33 Study of Exchange of Travoprost Intraocular Implant
Open Angle Glaucoma
Primary: Ocular Safety — 13 subjects
Phase 2 N=10 Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
Alcohol Dependence
Primary: Change in Percent Heavy Drinking Days — -25.962 percentage of days — p=0.008
Phase 2 N=30 Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Safety of Intravitreal Injection of hRPC — 15; 6; 6; 2 Participants
Phase 2 N=427 Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Change From Baseline to Month 6 in the Modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) Score — -3.2; -3.41; -2.84; -4.04 score on a scale — p=0.4749
Phase 2 N=20 Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Acute Myeloid Leukemia
Primary: Number of Patients With 2-year Relapse Risk — 10 Participants
Phase 2 N=252 A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
Alzheimer's Disease
Primary: Period A: Annualized Rate of Change in the Autosomal-Dominant Alzheimer's Disease (API ADAD) Composite Cognitive Test Total Score — -1.10; -1.42 points on scale per year…
Phase 2 N=62 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
Hypertension
Primary: Change in Mean Systolic Blood Pressure — -15.65; -10.87 mm Hg — p=0.114